Get Premium to unlock powerful stock data

Deerfield Management Company, L.p. (series C) Buys Nuvalent Inc, Sema4 Holdings Corp, Neurocrine Biosciences Inc, Sells Zimmer Biomet Holdings Inc, , Quidel Corp

Author's Avatar
insider
Nov 17, 2021
Article's Main Image
Investment company Deerfield Management Company, L.p. (series C) (Current Portfolio) buys Nuvalent Inc, Sema4 Holdings Corp, Neurocrine Biosciences Inc, Glaukos Corp, Aerie Pharmaceuticals Inc, sells Zimmer Biomet Holdings Inc, , Quidel Corp, Galapagos NV, Reata Pharmaceuticals Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Deerfield Management Company, L.p. (series C). As of 2021Q3, Deerfield Management Company, L.p. (series C) owns 111 stocks with a total value of $3.6 billion. These are the details of the buys and sells.

For the details of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s stock buys and sells, go to https://www.gurufocus.com/guru/deerfield+management+company%2C+l.p.+%28series+c%29/current-portfolio/portfolio

These are the top 5 holdings of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
  1. Nuvalent Inc (NUVL) - 19,341,024 shares, 12.13% of the total portfolio. New Position
  2. Viatris Inc (VTRS) - 18,824,000 shares, 7.09% of the total portfolio.
  3. AdaptHealth Corp (AHCO) - 8,103,792 shares, 5.25% of the total portfolio. Shares added by 10.20%
  4. CareMax Inc (CMAX) - 16,778,750 shares, 4.51% of the total portfolio.
  5. Neurocrine Biosciences Inc (NBIX) - 1,142,415 shares, 3.05% of the total portfolio. Shares added by 57.57%
New Purchase: Nuvalent Inc (NUVL)

Deerfield Management Company, L.p. (series C) initiated holding in Nuvalent Inc. The purchase prices were between $18.25 and $38.35, with an estimated average price of $29.21. The stock is now traded at around $27.500000. The impact to a portfolio due to this purchase was 12.13%. The holding were 19,341,024 shares as of 2021-09-30.

New Purchase: Sema4 Holdings Corp (SMFR)

Deerfield Management Company, L.p. (series C) initiated holding in Sema4 Holdings Corp. The purchase prices were between $0 and $12.25, with an estimated average price of $9.55. The stock is now traded at around $7.290000. The impact to a portfolio due to this purchase was 2.92%. The holding were 13,848,488 shares as of 2021-09-30.

New Purchase: Glaukos Corp (GKOS)

Deerfield Management Company, L.p. (series C) initiated holding in Glaukos Corp. The purchase prices were between $47.43 and $84.23, with an estimated average price of $55.92. The stock is now traded at around $50.110000. The impact to a portfolio due to this purchase was 0.83%. The holding were 619,000 shares as of 2021-09-30.

New Purchase: Vincerx Pharma Inc (VINC)

Deerfield Management Company, L.p. (series C) initiated holding in Vincerx Pharma Inc. The purchase prices were between $11.6 and $17.39, with an estimated average price of $14.62. The stock is now traded at around $12.700000. The impact to a portfolio due to this purchase was 0.62%. The holding were 1,379,310 shares as of 2021-09-30.

New Purchase: Montes Archimedes Acquisition Corp (MAAC)

Deerfield Management Company, L.p. (series C) initiated holding in Montes Archimedes Acquisition Corp. The purchase prices were between $9.35 and $10.41, with an estimated average price of $9.93. The stock is now traded at around $9.350000. The impact to a portfolio due to this purchase was 0.52%. The holding were 2,000,000 shares as of 2021-09-30.

New Purchase: Erasca Inc (ERAS)

Deerfield Management Company, L.p. (series C) initiated holding in Erasca Inc. The purchase prices were between $17.43 and $24.34, with an estimated average price of $20.69. The stock is now traded at around $19.550000. The impact to a portfolio due to this purchase was 0.46%. The holding were 786,660 shares as of 2021-09-30.

Added: Neurocrine Biosciences Inc (NBIX)

Deerfield Management Company, L.p. (series C) added to a holding in Neurocrine Biosciences Inc by 57.57%. The purchase prices were between $86.18 and $99.03, with an estimated average price of $94.54. The stock is now traded at around $88.270000. The impact to a portfolio due to this purchase was 1.11%. The holding were 1,142,415 shares as of 2021-09-30.

Added: Aerie Pharmaceuticals Inc (AERI)

Deerfield Management Company, L.p. (series C) added to a holding in Aerie Pharmaceuticals Inc by 260.44%. The purchase prices were between $11.32 and $16.63, with an estimated average price of $14.64. The stock is now traded at around $11.570000. The impact to a portfolio due to this purchase was 0.68%. The holding were 2,977,020 shares as of 2021-09-30.

Added: Day One Biopharmaceuticals Inc (DAWN)

Deerfield Management Company, L.p. (series C) added to a holding in Day One Biopharmaceuticals Inc by 108.89%. The purchase prices were between $20 and $27.92, with an estimated average price of $24. The stock is now traded at around $21.380000. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,710,730 shares as of 2021-09-30.

Added: Meridian Bioscience Inc (VIVO)

Deerfield Management Company, L.p. (series C) added to a holding in Meridian Bioscience Inc by 44.85%. The purchase prices were between $17.35 and $22.5, with an estimated average price of $19.97. The stock is now traded at around $20.340000. The impact to a portfolio due to this purchase was 0.34%. The holding were 2,063,083 shares as of 2021-09-30.

Added: Brookdale Senior Living Inc (BKD)

Deerfield Management Company, L.p. (series C) added to a holding in Brookdale Senior Living Inc by 59.27%. The purchase prices were between $5.87 and $8.59, with an estimated average price of $7.15. The stock is now traded at around $6.920000. The impact to a portfolio due to this purchase was 0.34%. The holding were 5,252,800 shares as of 2021-09-30.

Added: Cytokinetics Inc (CYTK)

Deerfield Management Company, L.p. (series C) added to a holding in Cytokinetics Inc by 24.12%. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $39.240000. The impact to a portfolio due to this purchase was 0.3%. The holding were 1,536,758 shares as of 2021-09-30.

Sold Out: Zimmer Biomet Holdings Inc (ZBH)

Deerfield Management Company, L.p. (series C) sold out a holding in Zimmer Biomet Holdings Inc. The sale prices were between $140.44 and $163.52, with an estimated average price of $151.62.

Sold Out: (CNST)

Deerfield Management Company, L.p. (series C) sold out a holding in . The sale prices were between $33.9 and $33.99, with an estimated average price of $33.95.

Sold Out: Quidel Corp (QDEL)

Deerfield Management Company, L.p. (series C) sold out a holding in Quidel Corp. The sale prices were between $114.31 and $157.32, with an estimated average price of $134.41.

Sold Out: Galapagos NV (GLPG)

Deerfield Management Company, L.p. (series C) sold out a holding in Galapagos NV. The sale prices were between $52.17 and $70.2, with an estimated average price of $59.52.

Sold Out: Reata Pharmaceuticals Inc (RETA)

Deerfield Management Company, L.p. (series C) sold out a holding in Reata Pharmaceuticals Inc. The sale prices were between $100 and $143.02, with an estimated average price of $117.47.

Sold Out: Owens & Minor Inc (OMI)

Deerfield Management Company, L.p. (series C) sold out a holding in Owens & Minor Inc. The sale prices were between $30.87 and $47.58, with an estimated average price of $39.39.



Here is the complete portfolio of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). Also check out:

1. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s Undervalued Stocks
2. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s Top Growth Companies, and
3. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s High Yield stocks
4. Stocks that DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus